Laboratory challenges with cell-based NIPT

Author Archives: WebMast

Laboratory challenges with cell-based NIPT

GLOBAL UPDATES (ISPD) Ripudaman Singh1, Niels Uldbjerg2, Lotte Hatt1, Palle Schelde1, Ida Vogel3,4 ARCEDI Biotech ApS Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark Department of Clinical Genetics, Aarhus University Hospital, Denmark Center for Prenatal Diagnostics, Aarhus University Hospital, Denmark In accordance with ISPD policy, the authors of this article Lotte Hatt, Palle Schelde  Ripudaman Singh disclose […]

read more

Does Maternal Body Mass Index Affect the Quantity of Circulating Fetal Cells Available to Use for Cell-Based Noninvasive Prenatal Test in High-Risk Pregnancies?

Fetal Diagnosis and Therapy. Sept 2018 Kruckow S, Schelde P, Hatt L, Ravn K, Petersen OB, Uldbjerg N, Vogel I, Singh R. We present the first study that investigates the effect of maternal body mass index (BMI) on the quantity of circulating fetal cells available to use in cell-based noninvasive prenatal test (cbNIPT). cbNIPT has been proposed as a superior alternative to noninvasive prenatal […]

read more

Guest Symposium at ARCEDI Biotech ApS

read more

27-11-2017 PRESS RELEASE

ARCEDI BIOTECH TO PRESENT AT FIFTH ANNUAL ADVANCES IN PRENATAL MOLECULAR DIAGNOSTICS CONFERENCE – Additional Presentations and Panel Discussions Highlight Advances in Cell-Based Non-Invasive Prenatal Testing – Vejle, Denmark, November 27, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced that Ripudaman […]

read more

13-11-2017 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES LAUNCH OF FIRST AND ONLY NON-INVASIVE PRENATAL TESTING BASED ON FETAL CELLS IN MATERAL BLOOD IN DENMARK – Comparative Non-Invasive Alternative to Invasive “Gold-Standard” Testing – Vejle, Denmark, November 13, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced […]

read more

6-11-17 PRESSEMEDDELELSE (Dansk)

PRESSEMEDDELELSE Ny og lovende fosterdiagnostik er mere skånsom for gravide I fremtiden vil det måske blive muligt for gravide at undgå en moderkageprøve. En simpel blodprøve vil kunne give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. Mange gravide bliver bekymrede, hvis de får […]

read more

BREAKING – Simpel blodprøve kan erstatte moderkageprøve hos gravide

06. nov. 2017, 11:27 af Rizau Ny og lovende fosterdiagnostik er mere skånsom over for gravide, viser ny forskning. I fremtiden bliver det måske muligt for gravide at undgå en moderkageprøve. En simpel blodprøve kan give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. […]

read more

ARCEDI Biotech Readying Cell-Based NIPT for Commercialization as Clinical Studies Continue (GenomeWeb)

Oct 30, 2017 Julia Karow NEW YORK (GenomeWeb) – Arcedi Biotech of Denmark has been collaborating with six Danish hospitals to clinically validate its technology for isolating circulating fetal cells from maternal blood and analyzing their DNA for noninvasive prenatal diagnostics. Arcedi hopes to commercialize the technology in the near future through a large diagnostic […]

read more

On the road to replacing invasive testing with cell‐based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism

Prenatal Diagnosis. 2017 Nov;37(11):1120-1124 Vestergaard EM, Singh R, Schelde P, Hatt L, Ravn K, Christensen R, Lildballe DL, Petersen OB, Uldbjerg N, Vogel I Objective: Trophoblastic fetal cells harvested from maternal blood have the capacity to be used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT). Potentially, this will result in increased resolution for detection of subchromosomal aberrations due to high […]

read more

12-10-17 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES PUBLICATION HIGHLIGHTING SUCCESS OF CUTTING-EDGE CELL-BASED NONINVASIVE PRENATAL TESTING TO DETECT ANEUPLOIDY AND SUBCHROMOSOMAL ABNORMALITIES IN FIRST TRIMESTER PREGNANCIES – Preliminary Results Identical to Invasive “Gold-Standard” Testing – Vejle, Denmark, October 12, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, […]

read more